INTEGRAL DIAGNOSTICS LIMITED (IDX)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

IDX - INTEGRAL DIAGNOSTICS LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 4.37
Index: ASX300 | ALL-ORDS

Integral Diagnostics is an Australian healthcare services company providing diagnostic imaging services to medical practitioners in Australia and New Zealand. It has been a listed company since 2015.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$1.86

07 Dec
2023

0.020

OPEN

$1.82

1.09%

HIGH

$1.90

1,101,711

LOW

$1.81

TARGET
$2.238 20.3% upside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CYC . EBR . EMV . EYE . FPH . HLA . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RMD . SOM . TRJ . UBI . VHT . VTI .
FNARENA'S MARKET CONSENSUS FORECASTS
IDX: 1
Title FY22
Actual		 FY23
Actual		 FY24
Forecast		 FY25
Forecast
EPS (cps) xxx 10.8 7.6 xxx
DPS (cps) xxx 6.0 5.6 xxx
EPS Growth xxx 54.2% - 29.7% xxx
DPS Growth xxx - 14.3% - 6.7% xxx
PE Ratio xxx N/A 24.7 xxx
Dividend Yield xxx N/A 3.0% xxx
Div Pay Ratio(%) xxx 55.8% 74.0% xxx

Dividend yield today if purchased 3 years ago: 1.43%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 3.21

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 31/08 - ex-div 3.5c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2023 FactSet UK Limited. All rights reserved
Title 201820192020202120222023
EPS Basic xxxxxxxxxxxxxxx10.8
DPS All xxxxxxxxxxxxxxx6.0
Sales/Revenue xxxxxxxxxxxxxxx440.1 M
Book Value Per Share xxxxxxxxxxxxxxx160.1
Net Operating Cash Flow xxxxxxxxxxxxxxx71.4 M
Net Profit Margin xxxxxxxxxxxxxxx5.69 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201820192020202120222023
Return on Capital Employed xxxxxxxxxxxxxxx6.95 %
Return on Invested Capital xxxxxxxxxxxxxxx3.60 %
Return on Assets xxxxxxxxxxxxxxx3.09 %
Return on Equity xxxxxxxxxxxxxxx6.95 %
Return on Total Capital xxxxxxxxxxxxxxx5.63 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx14.8 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201820192020202120222023
Short-Term Debt xxxxxxxxxxxxxxx17 M
Long Term Debt xxxxxxxxxxxxxxx348 M
Total Debt xxxxxxxxxxxxxxx365 M
Goodwill - Gross xxxxxxxxxxxxxxx444 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx34 M
Price To Book Value xxxxxxxxxxxxxxx2.05

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201820192020202120222023
Capex xxxxxxxxxxxxxxx44.0 M
Capex % of Sales xxxxxxxxxxxxxxx10.00 %
Cost of Goods Sold xxxxxxxxxxxxxxx342 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx58 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.5

No. Of Recommendations

4
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgan Stanley

xx/xx/xxxx

3

xxxxxxx xx xxxxx-xxxxxx xxxx xxxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

xx/xx/xxxx

1

xxxxxxx xx xxx xxxx xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

06/11/2023

1

Outperform

$2.55

37.10%

While Integral Diagnostics' Australian revenue growth for the 1Q was in line with Macquarie's forecast, New Zealand revenue growth and earnings disappointed. A favourable medium-to longer-term outlook is envisaged, but materially negative EPS revisions are made over FY24-26.

Overall, the impacts of reduced staff availability/cost inflation in the quarter more than offset volume growth/indexation benefits, explains the analyst.

The target falls to $2.55 from $3.55 on the broker's EPS downgrades, revised capex assumptions and updated risk-free rates. Outperform retained.

FORECAST
Macquarie forecasts a full year FY24 dividend of 5.00 cents and EPS of 7.30 cents.
Macquarie forecasts a full year FY25 dividend of 8.00 cents and EPS of 11.40 cents.

Citi

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >

IDX STOCK CHART

FNArena News on IDX

1
Rudi’s View: Bear&Bull Market To Continue (?) In 2024

Dec 06 2023 - Rudi's View
2
ESG Focus: The Little Big Things – 30-11-2023

Nov 30 2023 - ESG Focus
3
Rudi’s View: Quality In Stocks; What Is It Good For?

Nov 22 2023 - Rudi's View
4
In Case You Missed It – BC Extra Upgrades & Downgrades – 17-11-23

Nov 17 2023 - Weekly Reports
5
Australian Broker Call *Extra* Edition – Nov 16, 2023

Nov 16 2023 - Daily Market Reports

Latest Medical Equipment & Devices News

1
Dr Boreham’s Crucible: Pro Medicus

Oct 23 2023 - Australia
2
Dr Boreham’s Crucible: Cyclopharm

Oct 09 2023 - Small Caps
3
Dr Boreham’s Crucible: Painchek

Sep 11 2023 - Small Caps
4
Margins Signal Integral Diagnostics Recovery

Sep 07 2023 - Australia
5
ResMed: Finding A Base?

Aug 15 2023 - Technicals
6
August Turns ResMed Into Nigel NoMates

Aug 09 2023 - Australia
7
Dr Boreham’s Crucible: Lumos Diagnostics

Jun 19 2023 - Small Caps
8
Fisher & Paykel Healthcare: Lower Margin, Higher Spending

May 30 2023 - Australia
9
Dr Boreham’s Crucible: Impedimed

May 08 2023 - Small Caps
10
Treasure Chest: ResMed’s Benevolent Monopoly

May 01 2023 - Treasure Chest